Become a Member

AbbVie Inc. (ABBV)

Healthcare • Drug Manufacturers - General

37
Beobachten
$225,63
Price
0,00%
Change
398,77 Mrd. $
Market Cap
73,48
P/E Ratio

Neumann-Score Stock Analysis

37
out of 100
Beobachten
Valuation??/100
Profitability??/100
Growth??/100

Unlock Score Details

Become a member and get access to all analyses.

Become a Member

About AbbVie Inc.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to trea ...

CEO
Robert A. Michael
Employees
55.000
Country
US